Cholesterol control according to the presence of metabolic syndrome in coronary and diabetic patients. Relationship with non-alcoholic fatty liver disease.
OBJECTIVE
Metabolic syndrome (MS) is an association of cardiovascular risk factors that increases the risk of coronary disease or type 2 diabetes mellitus (DM2), and has also been associated with the presence of liver steatosis (LS). In this study the relation of MS and LS with cholesterol control was analyzed in very high cardiovascular risk patients (coronary patients and/or DM2).


METHODS
A cross-sectional epidemiological study including 6988 patients, from whom information was obtained on their characteristics, lipid profile and treatments.


RESULTS
4455 patients (65%) of the total study population had MS. Of MS criteria, high BP was the criterion most represented in the total population, while high TGs was the least. Within the total population, coronary patients showed a greater proportion of high BP, high TG and low HDL-c than those without coronary disease. Although no influence of MS was seen on the achievement of LDL-c targets (<70 mg/dL), the presence of high BP, high blood glucose and low HDL-c was related to poorer control of LDL-c. Finally, patients with MS showed a greater proportion of liver steatosis and this was associated in turn with poorer control of LDL-c.


CONCLUSIONS
The criteria for MS are closely related to cholesterol control. LS is more prevalent in patients with MS, and it is associated with poorer control of LDL-c. We should focus on the presence of MS in high and very high CV risk patients in order to improve their lipid control.
Cardiovascular Risk and Lipid Unit, Instituto de Investigaciones Sanitarias, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense Madrid, Red Investigación Cardiovascular (RIC), RD12/0042/0033, Instituto de Salud Carlos III, Spain.
Ana
A
Torres do Rego
Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain. Electronic address: leopisla@hotmail.com.
Leopoldo
L
Perez de Isla
Cardiology Department, Hospital del Tajo, Aranjuez, Madrid, Spain.
Adriana
A
Saltijeral Cerezo
Medical Department, Merck Sharp and Dohme, MSD España, Madrid, Spain.
Gustavo
G
Vitale
Medical Department, Merck Sharp and Dohme, MSD España, Madrid, Spain.
Alberto
A
Izarra
Cardiovascular Risk and Lipid Unit, Instituto de Investigaciones Sanitarias, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense Madrid, Red Investigación Cardiovascular (RIC), RD12/0042/0033, Instituto de Salud Carlos III, Spain.
Luis Antonio
LA
Alvarez-Sala Walther
D000368:Aged; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology*; D003925:Diabetic Angiopathies / Q000097:blood / Q000453:epidemiology*; D005260:Female; D006801:Humans; D024821:Metabolic Syndrome / Q000097:blood / Q000453:epidemiology*; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease / Q000453:epidemiology*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D014280:Triglycerides; D002784:Cholesterol
Cardiovascular risk control; Hypercholesterolemia; Liver steatosis; Metabolic syndrome